Start of the Certainty project on 1st December 2023

Certainty: A virtual twin of cellular immunotherapy for personalized cancer treatment

The Certainity project, launched on December 1, 2023, aims to develop a “virtual twin” in cancer immunotherapy, particularly for CAR T-cell treatments. This digital model integrates a patient’s clinical, molecular and cellular data to simulate disease progression and treatment options, with an initial focus on multiple myeloma. The EU-funded CERTAINTY project, led by Fraunhofer IZI, combines big data, machine learning and computer models to personalize cancer treatment. The project also takes socio-economic factors into account and prioritizes data protection.

Partners of the project:

• Fraunhofer-Gesellschaft, Germany
  • • Fraunhofer IZI (project coordination)
    • Fraunhofer SCAI
    • Fraunhofer IMW
• University of Leipzig Medical Center, Germany
• Singleron Biotechnologies GmbH, Germany
• Collaborate Project Management, Germany
• Myeloma Patients Europe AISBL, Belgium
• TriNetX Oncology GmbH, Germany
• Masaryk University, Czech Republic
• Information Technology for Translational Medicine, Luxembourg
• University Hospital of Würzburg, Germany
• Institut Curie, France
• University of Namur, Belgium
• Universitair Medisch Centrum (UMC) Utrecht, The Netherlands
• Charité – Universitätsmedizin Berlin, Germany
• European Society for Blood and Marrow Transplantation (EBMT), The Netherlands
• HealthTree Foundation, USA
• Roche Pharma AG, Switzerland

Back to News